Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of “Buy” from Analysts

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has been given an average recommendation of “Buy” by the six analysts that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $12.33.

RANI has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Rani Therapeutics in a research note on Friday, February 7th. Canaccord Genuity Group reissued a “buy” rating and issued a $9.00 price objective on shares of Rani Therapeutics in a report on Wednesday, February 26th.

Rani Therapeutics Stock Up 1.5 %

RANI opened at $1.36 on Friday. The company has a fifty day moving average of $1.51 and a two-hundred day moving average of $1.84. The stock has a market capitalization of $77.91 million, a price-to-earnings ratio of -1.28 and a beta of 0.14. Rani Therapeutics has a fifty-two week low of $1.24 and a fifty-two week high of $8.75. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60.

Hedge Funds Weigh In On Rani Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP acquired a new stake in shares of Rani Therapeutics in the 4th quarter worth $399,000. Takeda Pharmaceutical Co. Ltd. acquired a new stake in Rani Therapeutics during the fourth quarter worth about $278,000. Stifel Financial Corp raised its stake in Rani Therapeutics by 100.4% during the third quarter. Stifel Financial Corp now owns 269,768 shares of the company’s stock worth $583,000 after purchasing an additional 135,148 shares during the period. Two Sigma Advisers LP acquired a new position in Rani Therapeutics in the 4th quarter valued at about $151,000. Finally, Insigneo Advisory Services LLC purchased a new stake in shares of Rani Therapeutics in the 4th quarter valued at approximately $65,000. Hedge funds and other institutional investors own 30.19% of the company’s stock.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.